Glaucoma is a group of eye diseases in which the optic nerve, the cable that carries visual signals from your eye to your brain, is progressively damaged. The damage typically involves the death of retinal ganglion cells and their axons, which make up the optic nerve, and once those cells are gone they do not grow back. That is why glaucoma is called a leading cause of irreversible blindness. The disease usually develops silently over years, stealing peripheral vision first, so many people have no idea anything is wrong until significant damage has occurred.
How Fluid Buildup Damages the Optic Nerve
Your eye constantly produces a clear fluid called aqueous humor, which nourishes the lens and cornea and then drains out through two pathways in the front of the eye. About three-quarters of the fluid exits through a sieve-like tissue called the trabecular meshwork and into a small channel called Schlemm’s canal; the rest drains through an alternate route called the uveoscleral pathway.1PubMed Central. Aqueous humor dynamics: a review When either of these drainage routes becomes partially blocked or sluggish, fluid accumulates and pressure inside the eye rises.
That elevated pressure pushes on the optic nerve head at the back of the eye, where the nerve fibers exit toward the brain. The mechanical strain disrupts the transport of nutrients along the nerve fibers, triggers structural changes in the surrounding tissue, and eventually causes the retinal ganglion cells to die off.2PubMed Central. Imaging Retinal Ganglion Cell Death and Dysfunction in Glaucoma The characteristic “cupping” an eye doctor sees when looking at the optic disc is the visible result of those lost nerve fibers. Vision loss starts at the edges and creeps inward, which is why you can have substantial damage before noticing anything wrong with your central eyesight.
Types of Glaucoma
Primary Open-Angle Glaucoma
This is the most common form worldwide. The drainage angle where the iris meets the cornea stays physically open, but the trabecular meshwork becomes less efficient at letting fluid pass through. Pressure climbs gradually, and damage accumulates over months to years without pain or obvious symptoms. Because it is so slow and painless, open-angle glaucoma is often called the “silent thief of sight.”
Primary Angle-Closure Glaucoma
In angle-closure glaucoma, the iris itself physically blocks the drainage pathway. The most well-known trigger is pupillary block, where the iris and lens press together and trap fluid behind the iris. The pressure pushes the iris forward into contact with the trabecular meshwork, closing the drain. Other anatomical factors can also narrow the angle, including a thicker peripheral iris, an anteriorly positioned ciliary body, or a condition called plateau iris.3PubMed Central. Differences and Similarities Between Primary Open Angle Glaucoma and Primary Angle-Closure Glaucoma An acute angle-closure attack, unlike open-angle glaucoma, is an emergency: eye pressure spikes suddenly, causing severe eye pain, headache, nausea, and blurred vision with halos around lights. Without rapid treatment, permanent vision loss can happen within hours.
The structural differences between the two types are measurable. Studies using high-resolution imaging have found that people with angle-closure glaucoma tend to have a shorter trabecular meshwork compared to those with open-angle glaucoma, which may help explain why their drainage angle is more vulnerable to obstruction.4PubMed. Trabecular Meshwork Height in Primary Open-Angle Glaucoma Versus Primary Angle-Closure Glaucoma The two types also leave different fingerprints on the retina and visual field, with open-angle patients showing more thinning in certain retinal nerve fiber layers and more upper-field visual loss, while angle-closure patients show distinct patterns in other regions.5PubMed Central. Comparison of Structural and Functional Features in Primary Angle-Closure and Open-Angle Glaucomas
Normal-Tension Glaucoma
Some people develop the same optic nerve damage and visual field loss seen in typical glaucoma, yet their eye pressure never rises above the statistically normal range. This form, called normal-tension glaucoma, suggests that factors beyond pressure play a role. Vascular problems, reduced blood flow to the optic nerve, and individual susceptibility of the nerve cells are all suspected contributors. Interestingly, studies looking at blood vessel function in people with normal-tension glaucoma have found no obvious differences in circulation at rest compared to people without the disease, which suggests that any vascular problems may only show up under physiological stress.6PubMed Central. Vascular Dysregulation in Normal-Tension Glaucoma Is Not Affected by Structure and Function of the Microcirculation or Macrocirculation at Rest Normal-tension glaucoma is still treated by lowering eye pressure, because even modest reductions slow progression in many patients.
Secondary Glaucoma
When another condition causes the pressure to rise, it is called secondary glaucoma. The list of possible triggers is long: eye injuries, intraocular surgery (especially cataract surgery and corneal grafts), inflammation inside the eye, retinal vascular disease, and prolonged use of corticosteroid eye drops.7PubMed. Secondary glaucoma Two common culprits deserve special mention. In pseudoexfoliation syndrome, fibrillar deposits accumulate on structures inside the eye and clog the trabecular meshwork. In pigment dispersion syndrome, pigment granules flake off the back of the iris and settle in the drainage tissue, creating a similar blockage.8PubMed. Secondary glaucoma: Toward interventions based on molecular underpinnings Treatment targets both the underlying condition and the elevated pressure.
Who Is at Risk
Age is the single biggest risk factor. Glaucoma becomes increasingly common after age 40 and rises sharply after 60. Family history matters too: having a parent or sibling with glaucoma raises your own risk substantially, and genetic research has identified specific genes involved. The myocilin gene, for instance, encodes a protein expressed heavily in the trabecular meshwork, and mutations that cause the protein to misfold inside those drainage cells are linked to open-angle glaucoma.9PubMed Central. Myocilin-associated Glaucoma: A Historical Perspective and Recent Research Progress
Race and ethnicity also influence risk in ways researchers are still working to fully understand. People of African and Latin American descent face a higher prevalence of open-angle glaucoma, tend to develop it earlier, progress faster, and have higher rates of blindness from the disease compared to people of European descent.10PubMed Central. Racial Disparities in Glaucoma: From Epidemiology to Pathophysiology A large Canadian study found that Black individuals had higher average eye pressure and roughly two-and-a-half times the odds of reporting glaucoma compared to White individuals, even after adjusting for socioeconomic factors, behavior, and health conditions.11Heliyon. Exploring ethnic and racial differences in intraocular pressure and glaucoma: The Canadian Longitudinal Study on aging People of East and Southeast Asian descent, meanwhile, are more prone to angle-closure glaucoma, likely because of differences in eye anatomy.
Other well-established risk factors include high myopia (nearsightedness), thin corneas, low blood pressure, and diabetes. Having high eye pressure alone does not mean you have glaucoma; plenty of people with above-average pressure never develop optic nerve damage, and as normal-tension glaucoma shows, some people develop the disease at statistically normal pressures.
How Glaucoma Is Detected
Because glaucoma causes no symptoms until it is fairly advanced, detection depends on regular comprehensive eye exams. Several tests work together:
- Tonometry: measures the pressure inside your eye. The gold-standard instrument, developed by Hans Goldmann around 1950, flattens a tiny area of the cornea and remains the most widely used tonometer in the world.12PubMed. A history of intraocular pressure and its measurement
- Ophthalmoscopy: lets the doctor look directly at the optic nerve head to check for the cupping and thinning that signal damage.
- Visual field testing: maps your peripheral vision to detect blind spots you may not have noticed.
- Gonioscopy: uses a mirrored lens placed on the eye to inspect the drainage angle and determine whether it is open or narrow.
Optical coherence tomography, commonly called OCT, has become a cornerstone of glaucoma management. It uses light waves to produce high-resolution cross-sectional images of the retina, allowing your doctor to measure the thickness of the retinal nerve fiber layer and ganglion cell layer with remarkable precision.13PubMed Central. Clinical Utility of Optical Coherence Tomography in Glaucoma A large meta-analysis found that OCT scans of the average retinal nerve fiber layer thickness had strong diagnostic accuracy for glaucoma, and combining OCT structural data with visual field testing can detect disease progression faster than either method alone.14PLoS ONE. Optical coherence tomography for glaucoma diagnosis: An evidence based meta-analysis15PubMed Central. Combining optical coherence tomography with visual field data to rapidly detect disease progression in glaucoma: a diagnostic accuracy study
Eye Drops and Medications
For most people, treatment starts with prescription eye drops. The goal is not to cure the disease but to lower eye pressure enough to slow or halt further nerve damage. Different classes of drops work through different mechanisms: some reduce how much fluid the eye produces, while others help the fluid drain out more efficiently.
Prostaglandin analogs are usually the first choice. They work by opening up the uveoscleral drainage pathway, lowering eye pressure by roughly a quarter to a third with just one drop at bedtime. That once-daily convenience matters, because the more complex the dosing schedule, the harder it is for people to keep up with their drops. Other drug classes, including beta-blockers, alpha agonists, and carbonic anhydrase inhibitors, are added or substituted depending on how well the initial drops work and what side effects a patient experiences.
Sticking to a daily drop routine sounds simple, but in practice many people struggle. Research has found that roughly a quarter to a third of glaucoma patients do not take their medication consistently enough, with factors like older age, lower income, lack of health insurance, and more years living with the disease all predicting worse adherence. Since vision loss from missed doses is gradual and invisible in day-to-day life, it is easy to fall behind without realizing the consequences.
Laser Treatment
Selective laser trabeculoplasty, or SLT, is a quick in-office procedure that uses short pulses of low-energy laser light aimed at the trabecular meshwork. Rather than burning holes in the tissue, SLT triggers a biological remodeling process. The laser energy stimulates an immune response in the meshwork, attracts cleanup cells to the tissue, loosens the structural matrix, and improves fluid flow through Schlemm’s canal.16PubMed Central. Mechanism of selective laser trabeculoplasty: a systemic review The procedure takes a few minutes per eye, and unlike older laser techniques, SLT does not cause visible scarring, which means it can be repeated if the effect fades over time.
SLT is increasingly used as a first-line treatment rather than a backup when drops fail. Clinical trials have shown it can match or even outperform drops in early open-angle glaucoma, and some patients can delay or avoid medications altogether. For angle-closure glaucoma, a different laser procedure called laser peripheral iridotomy creates a tiny hole in the iris to relieve the pupillary block that traps fluid behind it.
Surgical Options
When drops and laser treatment are not enough to control pressure, surgery creates a new drainage pathway or implants a device to keep fluid moving out of the eye. Traditional trabeculectomy involves making a small flap in the white of the eye under the upper eyelid, allowing fluid to seep out into a space beneath the conjunctiva where the body absorbs it. It can bring pressure down substantially, but it carries risks including infection, excessive fluid drainage (called hypotony), and scarring that can close the new pathway over time.
Glaucoma drainage devices, small tubes connected to a plate sutured to the outer surface of the eye, offer an alternative, especially for eyes where trabeculectomy has failed or is likely to scar shut. In cases of juvenile open-angle glaucoma where a first trabeculectomy had already failed, both a second trabeculectomy and drainage-device implantation achieved similar success rates over five years, though drainage-device patients tended to need more medications afterward.17PubMed. Outcomes of Second Trabeculectomy Versus Glaucoma Drainage Device in Juvenile Open Angle Glaucoma After Primary Trabeculectomy Failure About a quarter of patients in both groups eventually required a third operation. Complications from drainage devices can include tube exposure, inflammation, and low pressure, though serious complications remain uncommon.18PubMed Central. Long-Term Surgical Outcomes of Glaucoma Drainage Implants in Eyes with Preoperative Intraocular Pressure Less than 19 mmHg
A newer category called minimally invasive glaucoma surgery, or MIGS, uses tiny devices inserted through the eye’s natural drainage system. MIGS devices that work through Schlemm’s canal tend to produce a modest drop in pressure with a favorable safety profile, making them a good fit for people with mild to moderate disease who want to reduce their medication load. Devices placed in different locations, such as beneath the conjunctiva or in the space behind the iris, can achieve bigger pressure reductions, though they may carry additional risks like excessive fluid drainage.19PubMed Central. Minimally invasive glaucoma surgery (MIGS) devices: risks, benefits and suitability While MIGS devices generally do not match the pressure-lowering power of trabeculectomy, they fill an important gap for patients who need more than drops but are not yet candidates for major surgery.20PubMed Central. Systematic Literature Review of Clinical and Economic Outcomes of Micro-Invasive Glaucoma Surgery (MIGS) in Primary Open-Angle Glaucoma
Glaucoma in Children
Glaucoma is not just an adult disease. Primary congenital glaucoma, though rare, appears in infancy and early childhood when the eye’s drainage system has not developed properly. A baby with congenital glaucoma may have tearing, light sensitivity, an unusually large or cloudy cornea, and eyes that appear larger than normal because the still-pliable infant eye stretches under elevated pressure. Unlike adult glaucoma, where drops are usually the first step, early surgery is the definitive treatment for congenital glaucoma because the underlying problem is a structural defect that medication alone cannot fix.21PubMed Central. Surgical management in primary congenital glaucoma: four debates The most common procedure, goniotomy, opens the malformed drainage tissue under direct visualization. With timely surgery, many children retain useful vision, though lifelong monitoring is essential because the eye can develop new problems as it grows.
How Glaucoma Affects Daily Life
The clinical measurements of visual field loss and nerve fiber thinning translate into real difficulties in everyday activities. People with bilateral glaucoma commonly report trouble reading, walking safely, and driving. Research consistently links the disease with bumping into objects, slower walking speed, increased risk of falls, and both limiting and stopping driving entirely.22PubMed Central. Glaucoma and Disability: Which tasks are affected, and at what stage of disease? Beyond physical tasks, glaucoma has psychological and financial impacts. The chronic nature of the disease, the knowledge that lost vision will not return, the burden of daily drops, and the cost of ongoing treatment all contribute to anxiety and reduced quality of life for both patients and their caregivers.23Journal of Glaucoma. Measuring Disability in Glaucoma
These effects tend to worsen in a stepwise fashion as the disease progresses. In early glaucoma, most people function normally and may not notice any visual change. Moderate glaucoma begins to interfere with activities that require a wide visual field, like driving and navigating unfamiliar places. Advanced glaucoma can make even basic tasks like reading and recognizing faces genuinely difficult.
Lifestyle Factors That May Help
Beyond prescribed treatments, certain lifestyle factors show promise as complements. Aerobic exercise appears to be associated with both lower eye pressure and neuroprotective effects on the optic nerve. Mindfulness-based practices have been linked to pressure reductions and possible nerve-cell protection as well. Nicotinamide, a form of vitamin B3, has shown early signals of neuroprotection and short-term improvement in visual function in glaucoma patients.24PubMed Central. From bench to behaviour: The role of lifestyle factors on intraocular pressure, neuroprotection, and disease progression in glaucoma Caffeine, a common concern among patients, causes mild, temporary pressure bumps that most researchers consider clinically insignificant.
None of these replace medical treatment. But they represent a shift in how the field thinks about glaucoma management, moving beyond pure pressure control toward strategies that also aim to protect the nerve cells directly.
Sustained Drug Delivery and Gene Therapy
The biggest practical weakness of glaucoma treatment is that it depends on patients putting drops in their eyes every single day for the rest of their lives. Researchers have spent years trying to solve this problem with sustained-release drug delivery systems that eliminate or reduce the need for daily drops. Two such devices have reached FDA approval so far: Durysta, a tiny biodegradable implant placed inside the eye that slowly releases a prostaglandin analog over months, and iDose TR, which sits in the trabecular meshwork and delivers a continuous micro-dose of medication.25PubMed. Drug delivery systems in glaucoma – Current innovations and future perspectives Both are significant steps forward, though real-world adoption has been slowed by high costs and logistical hurdles.
Further down the pipeline, gene therapy aims to tackle glaucoma at a more fundamental level. Rather than managing pressure with drugs, the idea is to deliver genetic instructions directly to the cells involved, either to increase fluid drainage, protect retinal ganglion cells from dying, or reduce the mitochondrial stress that contributes to nerve damage. These approaches are still in early development, but they represent a shift toward treatments that could modify the disease itself rather than just managing one of its risk factors.26PubMed. Glaucoma – Next Generation Therapeutics: Impossible to Possible